

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/655,873 | | |
| | | Filing Date | September 5, 2003 | | |
| | | First Named Inventor | Shyam S. Mohapatra | | |
| | | Group Art Unit | 1632 | | |
| | | Examiner Name | | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | USF-182XC1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| UNL | R1 | KUMAR, M. et al. "Chitosan IFN-γ-pDNA nanoparticle (CIN) therapy for allergic asthma" <i>Genetic Vaccines and Therapy</i> , October 2003, 1(1):3. | |
| | R2 | | |
| | R3 | | |
| | R4 | | |
| | R5 | | |
| | R6 | | |
| | R7 | | |
| | R8 | | |
| | R9 | | |
| | R10 | | |
| | R11 | | |
| | R12 | | |
| | R13 | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 1/03/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|----|--------------------------|------------------------|------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/655,873 | |
| | | | Filing Date | September 5, 2003 | |
| | | | First Named Inventor | Shyam S. Mohapatra | |
| | | | Art Unit | 1632 | |
| | | | Examiner Name | | |
| Sheet | 1 | of | 5 | Attorney Docket Number | USF-182XC1 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| CDL | U1 | US-6,489,306 B2 | 12-03-2002 | Mohapatra et al. | All |
| | U2 | US-2003/0198624 A1 | 10-23-2003 | Mohapatra et al. | All |
| | U3 | US-2001/0006951 A1 | 07-05-2001 | Mohapatra et al. | All |
| | U4 | US- | | | |
| | U5 | US- | | | |
| | U6 | US- | | | |
| | U7 | US- | | | |
| | U8 | US- | | | |
| | U9 | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| CDL | F1 | WO 03/074561 A1 | 09-12-2003 | Univ. South Florida | All | |
| | F2 | | | | | |
| | F3 | | | | | |
| | F4 | | | | | |
| | F5 | | | | | |
| | F6 | | | | | |
| | F7 | | | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 1/03/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/655,873 | | |
| | | Filing Date | September 5, 2003 | | |
| | | First Named Inventor | Shyam S. Mohapatra | | |
| | | Group Art Unit | 1632 | | |
| | | Examiner Name | | | |
| Sheet | 2 | of | 5 | Attorney Docket Number | USF-182XC1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CDL | R1 | BARNES, P.J. "Cytokine-directed therapies for asthma" <i>J. Allergy Clin. Immunol.</i> , 2001, 108:S72-76. | |
| | R2 | BEHERA, A.K. <i>et al.</i> "Adenovirus-mediated interferon γ gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling" <i>Human Gene Therapy</i> , 2002, 13:1697-1709. | |
| | R3 | BORASCHI, D. <i>et al.</i> "Interferons inhibit LTC ₄ production in murine macrophages" <i>J. Immunol.</i> , 1987, 138:4341-4346. | |
| | R4 | BYRNES, A.A. <i>et al.</i> "Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity" <i>Eur. J. Immunol.</i> , 2001, 31:2026-2034. | |
| | R5 | CHEN, Q. <i>et al.</i> "Development of Th-1-type immune responses requires the type I cytokine receptor TCCR" <i>Nature</i> , 2000, 407:916-920. | |
| | R6 | COHEN, J. "IL-12 deaths: explanation and a puzzle" <i>Science</i> , 1995, 270:908. | |
| | R7 | DAINES, M.O. and HERSHEY, G. "A novel mechanism by which interferon- γ can regulate interleukin (IL-13) responses" <i>J. Biol. Chem.</i> , 2002, 277(12):10387-10393. | |
| | R8 | DENG, J.C. <i>et al.</i> "Transient transgenic expression of gamma interferon promotes <i>Legionella pneumophila</i> clearance in immunocompetent hosts" <i>Infection and Immunity</i> , 2001, 69(10):6382-6390. | |
| | R9 | FORD, J.G. <i>et al.</i> "IL-13 and IFN- γ : interactions in lung inflammation" <i>J. Immunol.</i> , 2001, 167:1769-1777. | |
| | R10 | GAVETT, S.H. <i>et al.</i> "Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice" <i>J. Exp. Med.</i> , 1995, 182:1527-1536. | |
| | R11 | GURUJEYALAKSHMI, G. and GIRI, S.N. "Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF- β and procollagen I and III gene expression" <i>Exp. Lung Res.</i> , 1995, 21:791-808. | |
| | R12 | HANSEN, G. <i>et al.</i> "Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation" <i>J. Clin. Invest.</i> , 1999, 103:175-183. | |
| | R13 | HANSEN, G. <i>et al.</i> "CD4 ⁺ T helper cells engineered to produce latent TGF- β 1 reverse allergen-induced airway hyperreactivity and inflammation" <i>J. Clin. Invest.</i> , 2000, 105:61-70. | |


| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
| | 1/03/05 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/655,873 | | |
| | | Filing Date | September 5, 2003 | | |
| | | First Named Inventor | Shyam S. Mohapatra | | |
| | | Group Art Unit | 1632 | | |
| | | Examiner Name | | | |
| Sheet | 3 | of | 5 | Attorney Docket Number | USF-182XC1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| UD | R14 | HASBOLD, J. <i>et al.</i> "Integrating signals from IFN- γ and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a" <i>J. Immunol.</i> , 1999, 163:4175-4181. | |
| | R15 | HASKO, G. and SZABO, C. "IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses" <i>Brit. J. Pharm.</i> , 1999, 127:1295-1304. | |
| | R16 | HE, T-C. <i>et al.</i> "A simplified system for generating recombinant adenoviruses" <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:2509-2514. | |
| | R17 | KAPLAN, M.H. <i>et al.</i> "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice" <i>Nature</i> , 1996, 382:174-177. | |
| | R18 | KAPLAN, M.H. <i>et al.</i> "A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells" <i>J. Exp. Med.</i> , 1998, 188(6):1191-1196. | |
| | R19 | KIRKWOOD, J.M. <i>et al.</i> "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684" <i>J. Clin. Oncology</i> , 1996, 14(1):7-17. | |
| | R20 | KITAGAWA, M. <i>et al.</i> "Interferon- γ enhances interleukin 12 production in rheumatoid synovial cells via CD40-CD154 dependent and independent pathways" <i>J. Rheumatology</i> , 2001, 28:1764-1771. | |
| | R21 | KUMAR, M. <i>et al.</i> "Intranasal IFN- γ gene transfer protects BALB/c mice against respiratory syncytial virus infection" <i>Vaccine</i> , 2000, 18:558-567. | |
| | R22 | KUMAR, M. <i>et al.</i> "IFN- γ and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy" <i>J. Allergy Clin. Immunol.</i> , 2001, 108:402-408. | |
| | R23 | LACK, G. <i>et al.</i> "Nebulized but not parenteral IFN- γ decreases IgE production and normalizes airways function in a murine model of allergen sensitization" <i>J. Immunol.</i> , 1994, 152:2546-2554. | |
| | R24 | LI, X-M. <i>et al.</i> "Mucosal IFN- γ gene transfer inhibits pulmonary allergic responses in mice" <i>J. Immunol.</i> , 1996, 157:3216-3219. | |
| | R25 | LIGHVANI, A.A. <i>et al.</i> "T-bet is rapidly induced by interferon- γ in lymphoid and myeloid cells" <i>PNAS</i> , 2001, 98(26):15137-15142. | |
| | R26 | MATSUME, H. <i>et al.</i> "Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness" <i>J. Immunol.</i> , 2000, 164:6583-6592. | |


| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 11/03/05 |
|--------------------|--|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/655,873 | | |
| | | Filing Date | September 5, 2003 | | |
| | | First Named Inventor | Shyam S. Mohapatra | | |
| | | Group Art Unit | 1632 | | |
| | | Examiner Name | | | |
| Sheet | 4 | of | 5 | Attorney Docket Number | USF-182XC1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| UX | R27 | MINSHALL, E.M. et al. "Eosinophil-associated TGF- β_1 mRNA expression and airways fibrosis in bronchial asthma" <i>Am. J. Respir. Cell Mol. Biol.</i> , 1997, 17:326-333. | |
| | R28 | MORRISON, D.F. and MURTAUGH, M.P. "Adenovirus-mediated expression of interleukin-1 receptor antagonist in swine cells in vitro and in vivo" <i>Veterinary Immunol. and Immunopathology</i> , 2001, 78:71-81. | |
| | R29 | MOSMANN, T.R. and COFFMAN, R.L. "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties" <i>Ann. Rev. Immunol.</i> , 1989, 7:145-173. | |
| | R30 | MULLEN, A.C. et al. "Role of T-bet in commitment of T _H 1 cells before IL-12-dependent selection" <i>Science</i> , 2001, 292:1907-1909. | |
| | R31 | O'GARRA, A. and ARAI, N. "The molecular basis of T helper 1 and T helper 2 cell differentiation" <i>Cell Biol.</i> , 2000, 10:542-550. | |
| | R32 | OPPMANN, B. et al. "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12" <i>Immunity</i> , 2000, 13:715-725. | |
| | R33 | PIERKES, M. et al. "Decreases release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN- γ production of T cells" <i>J. Allergy Clin. Immunol.</i> , 1999, 103:326-332. | |
| | R34 | RANDOLPH, D.A. et al. "Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma" <i>J. Immunol.</i> , 1999, 162:2375-2383. | |
| | R35 | ROBINSON, D.S. et al. "Predominant T _H 2-like bronchoalveolar T-lymphocyte population in atopic asthma" <i>N. Engl. J. Med.</i> , 1992, 326:298-304. | |
| | R36 | RUDICK, R.A. et al. "Management of multiple sclerosis" <i>J. Engl. J. Med.</i> , 1997, 337(22):1604-1611. | |
| | R37 | SCHWARZE, J. et al. "Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice" <i>J. Allergy Clin. Immunol.</i> , 1998, 102:86-93. | |
| | R38 | STAMPFLI, M.R. et al. "GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice" <i>J. Clin. Invest.</i> , 1998, 102:1704-1714. | |
| | R39 | STIRLING, R.G. and CHUNG, K.F. "New immunological approaches and cytokine targets in asthma and allergy" <i>Eur. Respir. J.</i> , 2000, 16:1158-1174. | |


| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 1/03/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|--------------------|------------------------|------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/655,873 | | |
| | | Filing Date | September 5, 2003 | | |
| | | First Named Inventor | Shyam S. Mohapatra | | |
| | | Group Art Unit | 1632 | | |
| | | Examiner Name | | | |
| Sheet | 5 | of | 5 | Attorney Docket Number | USF-182XC1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| UDL | R40 | SUR, S. <i>et al.</i> "Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma" <i>Exp. Lung Res.</i> , 2000, 26:477-489. | |
| | R41 | TANG, C. <i>et al.</i> "Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN- γ -dependent mechanism" <i>J. Immunol.</i> , 2001, 166:1471-1481. | |
| | R42 | THIERFELDER, W.E. <i>et al.</i> "Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells" <i>Nature</i> , 1996, 382:171-174. | |
| | R43 | THIVIERGE, M. <i>et al.</i> "IL-13 and IL-4 up-regulated cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages" <i>J. Immunol.</i> , 2001, 167:2855-2860. | |
| | R44 | TRINCHIERI, G. "Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes" <i>Blood</i> , 1994, 84(12):4008-4027. | |
| | R45 | UMETSU, D.T. and DEKRUYFF, R.H. "T _{H1} and T _{H2} CD4 ⁺ cells in human allergic diseases" <i>J. Allergy Clin. Immunol.</i> , 1997, 100(1):1-6. | |
| | R46 | WALTER, D.M. <i>et al.</i> "IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity" <i>J. Immunol.</i> , 2001, 166:6392-6398. | |
| | R47 | WANG, I-M. <i>et al.</i> "An IFN- γ -inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages" <i>J. Immunol.</i> , 2000, 165:271-279. | |
| | R48 | ZABNER, J. <i>et al.</i> "Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis" <i>J. Clin. Invest.</i> , 1996, 97:1504-1511. | |
| | R49 | | |
| | R50 | | |
| | R51 | | |
| | R52 | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 1/53/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.